Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

511 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's Disease.
Galasko D, Farlow MR, Lucey BP, Honig LS, Elbert D, Bateman R, Momper J, Thomas R, Rissman RA, Pa J, Aslanyan V, Balasubramanian A, West T, Maccecchini M, Feldman HH. Galasko D, et al. Among authors: farlow mr. medRxiv [Preprint]. 2024 Mar 22:2024.03.20.24304638. doi: 10.1101/2024.03.20.24304638. medRxiv. 2024. PMID: 38562783 Free PMC article. Preprint.
Adding Recognition Discriminability Index to the Delayed Recall Is Useful to Predict Conversion from Mild Cognitive Impairment to Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative.
Russo MJ, Campos J, Vázquez S, Sevlever G, Allegri RF; Alzheimer's Disease Neuroimaging Initiative. Russo MJ, et al. Front Aging Neurosci. 2017 Mar 10;9:46. doi: 10.3389/fnagi.2017.00046. eCollection 2017. Front Aging Neurosci. 2017. PMID: 28344552 Free PMC article.
Prevalence and Clinical Implications of a β-Amyloid-Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease.
Erickson P, Simrén J, Brum WS, Ennis GE, Kollmorgen G, Suridjan I, Langhough R, Jonaitis EM, Van Hulle CA, Betthauser TJ, Carlsson CM, Asthana S, Ashton NJ, Johnson SC, Shaw LM, Blennow K, Andreasson U, Bendlin BB, Zetterberg H; ADNI Cohort. Erickson P, et al. JAMA Neurol. 2023 Jul 31;80(9):969-79. doi: 10.1001/jamaneurol.2023.2338. Online ahead of print. JAMA Neurol. 2023. PMID: 37523162 Free PMC article.
Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression.
Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen C, Wall AE, Carter SF, Schöll M, Choo IH, Grimmer T, Redolfi A, Nordberg A, Scheltens P, Drzezga A, Frisoni GB; Alzheimer's Disease Neuroimaging Initiative. Caroli A, et al. Neurology. 2015 Feb 3;84(5):508-15. doi: 10.1212/WNL.0000000000001209. Epub 2015 Jan 7. Neurology. 2015. PMID: 25568301 Free PMC article.
Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.
Savage MJ, Holder DJ, Wu G, Kaplow J, Siuciak JA, Potter WZ; Foundation for National Institutes of Health (FNIH) Biomarkers Consortium CSF Proteomics Project Team for Alzheimer's Disease Neuroimaging Initiative. Savage MJ, et al. J Alzheimers Dis. 2015;46(2):431-40. doi: 10.3233/JAD-142778. J Alzheimers Dis. 2015. PMID: 25790831 Free PMC article.
511 results